Cargando…

Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al

Detalles Bibliográficos
Autores principales: Zheng, Jieling, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157361/
https://www.ncbi.nlm.nih.gov/pubmed/35640929
http://dx.doi.org/10.1136/jitc-2022-004965
_version_ 1784718622528110592
author Zheng, Jieling
Zhang, Bin
author_facet Zheng, Jieling
Zhang, Bin
author_sort Zheng, Jieling
collection PubMed
description
format Online
Article
Text
id pubmed-9157361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91573612022-06-16 Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al Zheng, Jieling Zhang, Bin J Immunother Cancer Letter BMJ Publishing Group 2022-05-31 /pmc/articles/PMC9157361/ /pubmed/35640929 http://dx.doi.org/10.1136/jitc-2022-004965 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Zheng, Jieling
Zhang, Bin
Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title_full Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title_fullStr Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title_full_unstemmed Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title_short Correspondence on 'Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by Jazieh et al
title_sort correspondence on 'novel imaging biomarkers predict outcomes in stage iii unresectable non-small cell lung cancer treated with chemoradiation and durvalumab' by jazieh et al
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157361/
https://www.ncbi.nlm.nih.gov/pubmed/35640929
http://dx.doi.org/10.1136/jitc-2022-004965
work_keys_str_mv AT zhengjieling correspondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyjaziehetal
AT zhangbin correspondenceonnovelimagingbiomarkerspredictoutcomesinstageiiiunresectablenonsmallcelllungcancertreatedwithchemoradiationanddurvalumabbyjaziehetal